Literature DB >> 17657478

The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.

Jerry J Buccafusco1, Alvin V Terry, Scott J Webster, Daniel Martin, Elizabeth J Hohnadel, Kristy A Bouchard, Samantha E Warner.   

Abstract

RATIONALE: The scopolamine-reversal model is enjoying a resurgence of interest in clinical studies as a reversible pharmacological model for Alzheimer's disease (AD). The cognitive impairment associated with scopolamine is similar to that in AD. The scopolamine model is not simply a cholinergic model, as it can be reversed by drugs that are noncholinergic cognition-enhancing agents.
OBJECTIVES: The objective of the study was to determine relevance of computer-assisted operant-conditioning tasks in the scopolamine-reversal model in rats and monkeys.
MATERIALS AND METHODS: Rats were evaluated for their acquisition of a spatial reference memory task in the Morris water maze. A separate cohort was proficient in performance of an automated delayed stimulus discrimination task (DSDT). Rhesus monkeys were proficient in the performance of an automated delayed matching-to-sample task (DMTS).
RESULTS: The AD drug donepezil was evaluated for its ability to reverse the decrements in accuracy induced by scopolamine administration in all three tasks. In the DSDT and DMTS tasks, the effects of donepezil were delay (retention interval)-dependent, affecting primarily short delay trials. Donepezil produced significant but partial reversals of the scopolamine-induced impairment in task accuracies after 2 mg/kg in the water maze, after 1 mg/kg in the DSDT, and after 50 microg/kg in the DMTS task.
CONCLUSIONS: The two operant-conditioning tasks (DSDT and DMTS) provided data most in keeping with those reported in clinical studies with these drugs. The model applied to nonhuman primates provides an excellent transitional model for new cognition-enhancing drugs before clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657478     DOI: 10.1007/s00213-007-0887-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.

Authors:  R T Bartus
Journal:  Pharmacol Biochem Behav       Date:  1978-12       Impact factor: 3.533

2.  A computer-assisted cognitive test battery for aged monkeys.

Authors:  Jerry J Buccafusco; Alvin V Terry; Paul B Murdoch
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 3.  Drug discovery in dementia: the role of rodent models.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

Review 4.  Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease.

Authors:  M Rossor; L L Iversen
Journal:  Br Med Bull       Date:  1986-01       Impact factor: 4.291

5.  Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

Authors:  Natasja de Bruin; Bruno Pouzet
Journal:  Pharmacol Biochem Behav       Date:  2006-09-20       Impact factor: 3.533

6.  Visual attention deficits in Alzheimer's disease: an fMRI study.

Authors:  Jing Hao; Kuncheng Li; Ke Li; Dexuan Zhang; Wei Wang; Yanhui Yang; Bin Yan; Baoci Shan; Xiaolin Zhou
Journal:  Neurosci Lett       Date:  2005-09-02       Impact factor: 3.046

7.  Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.

Authors:  Ilga Misane; Sven Ove Ogren
Journal:  Neuropsychopharmacology       Date:  2003-02       Impact factor: 7.853

8.  Effects of scopolamine on matching to sample paradigm and related tests in human subjects.

Authors:  G Koller; W Satzger; M Adam; M Wagner; N Kathmann; M Soyka; R Engel
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

9.  Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential.

Authors:  John N Bain; Mark A Prendergast; Alvin V Terry; Stephen P Arneric; Mark A Smith; Jerry J Buccafusco
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

10.  Effects of NMDA modulation in scopolamine dementia.

Authors:  R W Jones; K A Wesnes; J Kirby
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

View more
  21 in total

Review 1.  Multifunctional receptor-directed drugs for disorders of the central nervous system.

Authors:  Jerry J Buccafusco
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Cholinergic modulation of working memory activity in primate prefrontal cortex.

Authors:  Xin Zhou; Xue-Lian Qi; Kristy Douglas; Kathini Palaninathan; Hyun Sug Kang; Jerry J Buccafusco; David T Blake; Christos Constantinidis
Journal:  J Neurophysiol       Date:  2011-07-27       Impact factor: 2.714

3.  Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory.

Authors:  Amit Reches; Naama Levy-Cooperman; Ilan Laufer; Revital Shani-Hershkovitch; Keren Ziv; Dani Kerem; Noga Gal; Yaki Stern; Guy Cukierman; Myroslava K Romach; Edward M Sellers; Amir B Geva
Journal:  J Mol Neurosci       Date:  2014-02-18       Impact factor: 3.444

4.  The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.

Authors:  Scott J Webster; Christina A Wilson; Chih-Hung Lee; Eric G Mohler; Alvin V Terry; Jerry J Buccafusco
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys.

Authors:  Ruifeng Liu; Jonathan Crawford; Patrick M Callahan; Alvin V Terry; Christos Constantinidis; David T Blake
Journal:  Curr Biol       Date:  2017-08-17       Impact factor: 10.834

6.  Scopolamine disrupts place navigation in rats and humans: a translational validation of the Hidden Goal Task in the Morris water maze and a real maze for humans.

Authors:  Jan Laczó; Hana Markova; Veronika Lobellova; Ivana Gazova; Martina Parizkova; Jiri Cerman; Tereza Nekovarova; Karel Vales; Sylva Klovrzova; John Harrison; Manfred Windisch; Kamil Vlcek; Jan Svoboda; Jakub Hort; Ales Stuchlik
Journal:  Psychopharmacology (Berl)       Date:  2016-11-24       Impact factor: 4.530

7.  The scopolamine model as a pharmacodynamic marker in early drug development.

Authors:  Robert A Lenz; Jeffrey D Baker; Charles Locke; Lynne E Rueter; Eric G Mohler; Keith Wesnes; Walid Abi-Saab; Mario D Saltarelli
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

8.  A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil.

Authors:  Susan J Bartko; Ignasi Vendrell; Lisa M Saksida; Timothy J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2010-11-18       Impact factor: 4.530

9.  Age-related cognitive deficits in rhesus monkeys mirror human deficits on an automated test battery.

Authors:  Alan H Nagahara; Tim Bernot; Mark H Tuszynski
Journal:  Neurobiol Aging       Date:  2008-08-28       Impact factor: 4.673

10.  A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2009-07-03       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.